Novavax's Late-Stage COVID Vaccine Trial in U.S. Delayed Again: Should Investors Worry?

There's a maxim in business that it's best to underpromise and overdeliver. The idea is that it's always better to deliver a pleasant surprise than an unpleasant one. But this isn't a maxim that Novavax (NASDAQ: NVAX) seems to be following.

On Monday, the biotech announced another delay in the initiation of a U.S. late-stage study evaluating COVID-19 vaccine candidate NVX-CoV2373. Should investors be worried?

Image source: Getty Images.

Continue reading

Source Fool.com